Search Results - therapeuticarea+%3e+oncology

561 Results Sort By:
T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies
Summary: The National Cancer Institute (NCI) seeks licensees for this invention comprising (1) a novel T cell receptor (TCR) specific to the E2 protein of Human papillomavirus (HPV) type 6 in the context of the human leukocyte antigen, HLA-B55, and (2) a panel of Cos7 cells expressing different HLA proteins for validation of T cell responses in immunotherapies...
Published: 7/28/2025   |   Inventor(s): Clint Allen, Scott Norberg
Keywords(s):  
Category(s): Application > Research Materials, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Collaboration Sought > Licensing
A conserved viral peptide for use in cancer immunotherapy
Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for viral peptide (CE1)-based therapeutics for HCC prevention and treatment. Description of Technology: Hepatocellular carcinoma (HCC) is a common and aggressive primary liver cancer. It develops mainly from at-risk individuals with underlying chronic...
Published: 7/28/2025   |   Inventor(s): Xin Wei Wang, Lichun Ma, Man Hsin Hung
Keywords(s):  
Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration
Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy
Summary: The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for NCI’s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines. Description of Technology: Current dendritic cell (DC)-based cancer vaccines are limited by impaired DC function due to cancer-driven...
Published: 7/15/2025   |   Inventor(s): Jay Berzofsky, Shweta Tiwary
Keywords(s):  
Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing
Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1
Summary: The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is actively seeking potential licensees interested in further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases. Description of Technology: Cellular...
Published: 7/14/2025   |   Inventor(s): Paul Love, Avik Dutta
Keywords(s):  
Category(s): Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology
Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling
This technology includes a micro-engineered “thyroid-on-a-chip” that combines human thyroid organoids with integrated micro-vasculature to replicate the gland’s native blood flow and 3-D architecture, enabling rapid, patient-specific drug screening. By permitting real-time perfusion of nutrients, hormones, and immune cells, the platform...
Published: 7/15/2025   |   Inventor(s): Anagha Rama Varma, Parnika Kant, Kaitlyn Sadtler, Parinaz Fathi, Nicole Morgan, Paniz Rezvan Sangsari, Madison Daminato
Keywords(s):  
Category(s): Application > Diagnostics, Application > Medical Devices, Application > Research Materials, Application > Therapeutics, ResearchProducts > Human Cell Lines, ResearchProducts > Research Equipment, TherapeuticArea > Endocrinology, TherapeuticArea > Immunology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing
Synergistic Interactions for Improved Cancer Treatment
Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy into a therapeutic for cancer. Description of Technology: Immunotherapy has emerged as a promising treatment...
Published: 6/27/2025   |   Inventor(s): Barbara Felber, George Pavlakis, Sevasti Karaliota, Dimitrios Stellas
Keywords(s):  
Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing
Establishment and characterization of the A 1847 human ovarian carcinoma line
Summary: The National Cancer Institute (NCI) seeks licensees for a tumorigenic cell line, A1847, from a patient with metastatic ovarian cancer. As a BRCA1 deficient cell line, it serves as a model to researchers studying cell cycle regulation, tumor suppression and effective drugs aiding in repair of DNA damage. Description of Technology: Mutations,...
Published: 6/27/2025   |   Inventor(s): Stuart Aaronson, Nelson Ellmore (Estate)
Keywords(s):  
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Research Materials
Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma
This technology includes a first-in-class synthetic peptide, angubindin-1, designed to temporarily relax the blood-brain barrier (BBB)—the tightly sealed network of brain blood vessel cells that normally blocks most drugs—from the inside. By binding the tricellular tight-junction protein angulin-1/LSR, the peptide creates a reversible “molecular...
Published: 6/13/2025   |   Inventor(s): Sadhana Jackson
Keywords(s):  
Category(s): Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Oncology, Collaboration Sought > Licensing
First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)
It is well documented in literature that activation of RXFP1 by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory...
Published: 5/30/2025   |   Inventor(s): Juan Marugan, Mark Henderson, Kenneth Wilson, Wenwei Huang, Wenjuan Ye, Noel Southall, Jiankang Jiang, Khalida Shamim, Bing Li, Alexander Agoulnik, Abhijeet Kapoor, Joshua Hutcheson, Ana Cabrera, Irina Agoulnik
Keywords(s):  
Category(s): Application > Therapeutics, Application > Research Materials, TherapeuticArea > Oncology, TherapeuticArea > Cardiology, TherapeuticArea > Pulmonology, TherapeuticArea > Dermatology, TherapeuticArea > Reproductive Health, TherapeuticArea > Geriatrics
Next-Generation 5-HT-2B Serotonin-Receptor Antagonists for Anti-Fibrotic & Cardiopulmonary Therapy
This technology includes a family of small-molecule antagonists that selectively block the 5-HT2B serotonin receptor—an upstream driver of tissue-remodeling—to address fibrotic, cardiopulmonary and related disorders. Built on a conformationally-locked “(N)-methanocarba” nucleoside scaffold, the compounds show nanomolar potency,...
Published: 5/14/2025   |   Inventor(s): Kenneth Jacobson, Dilip Tosh
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Cardiology, TherapeuticArea > Dermatology, TherapeuticArea > Immunology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Oncology, TherapeuticArea > Pulmonology, TherapeuticArea > Respiratory
1 2 3 4 5 6 7 8 9 10 ...